Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Arch Ital Urol Androl ; 93(1): 82-83, 2021 Mar 19.
Article in English | MEDLINE | ID: covidwho-1449006

ABSTRACT

Dear Editor, in recent years there has been an increase in the number of new cases of cancer. This increase, in part, is closely related to the increase in average life expectancy, as well as more accurate diagnostic techniques and well-defined screening programs. [...].


Subject(s)
COVID-19 , Health Promotion , Men's Health , Prostatic Neoplasms/prevention & control , Testicular Neoplasms/prevention & control , Foundations , Humans , Male
2.
Tumour Biol ; 43(1): 159-176, 2021.
Article in English | MEDLINE | ID: covidwho-1369645

ABSTRACT

The human TMPRSS2 gene is pathogenetically implicated in both coronaviral lung infection and prostate cancer, suggesting its potential as a drug target in both contexts. SARS-COV-2 spike polypeptides are primed by the host transmembrane TMPRSS2 protease, triggering virus fusion with epithelial cell membranes followed by an endocytotic internalisation process that bypasses normal endosomal activation of cathepsin-mediated innate immunity; viral co-opting of TMPRSS2 thus favors microbial survivability by attenuating host inflammatory responses. In contrast, most early hormone-dependent prostate cancers express TMPRSS2:ERG fusion genes arising from deletions that eliminate the TMPRSS2 coding region while juxtaposing its androgen-inducible promoter and the open reading frame of ERG, upregulating pro-inflammatory ERG while functionally disabling TMPRSS2. Moreover, inflammatory oxidative DNA damage selects for TMPRSS2:ERG-fused cancers, whereas patients treated with antiinflammatory drugs develop fewer of these fusion-dependent tumors. These findings imply that TMPRSS2 protects the prostate by enabling endosomal bypass of pathogens which could otherwise trigger inflammation-induced DNA damage that predisposes to TMPRSS2:ERG fusions. Hence, the high oncogenic selectability of TMPRSS2:ERG fusions may reflect a unique pro-inflammatory synergy between androgenic ERG gain-of-function and fusogenic TMPRSS2 loss-of-function, cautioning against the use of TMPRSS2-inhibitory drugs to prevent or treat early prostate cancer.


Subject(s)
COVID-19/pathology , Fertility , Genes, Tumor Suppressor , Inflammation/pathology , Prostatic Neoplasms/prevention & control , Serine Endopeptidases/metabolism , COVID-19/genetics , COVID-19/virology , Humans , Male , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , SARS-CoV-2/isolation & purification , Serine Endopeptidases/genetics
3.
Prostate Cancer Prostatic Dis ; 25(1): 55-57, 2022 03.
Article in English | MEDLINE | ID: covidwho-1275902

ABSTRACT

Prostate cancer affects a significant proportion of men worldwide. Evidence from genetic and clinical studies suggests that there may be a causal association between prostate cancer and the human papilloma virus (HPV). As HPV is a vaccine-preventable pathogen, the possibility of a role in prostate cancer causation may reinforce the importance of effective HPV vaccination campaigns. This is of particular relevance in light of the COVID-19 pandemic, which may have considerable effects on HPV vaccine uptake and distribution.


Subject(s)
Alphapapillomavirus , COVID-19 , Papillomavirus Infections , Papillomavirus Vaccines , Prostatic Neoplasms , COVID-19/epidemiology , COVID-19/prevention & control , Humans , Male , Pandemics/prevention & control , Papillomaviridae , Papillomavirus Infections/complications , Papillomavirus Infections/epidemiology , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Prostatic Neoplasms/epidemiology , Prostatic Neoplasms/etiology , Prostatic Neoplasms/prevention & control , Vaccination
4.
J Cancer Educ ; 37(5): 1460-1465, 2022 10.
Article in English | MEDLINE | ID: covidwho-1125869

ABSTRACT

This study aims to determine if younger men, across racial and ethnic groups, discussed the benefits/risks/harms of PSA screening with health care professionals. Publicly available data were obtained from the Health Information National Trends Survey https://hints.cancer.gov/ in March 2019. Cross-sectional analysis of 518 men between the ages of 18 and 49 years from men who completed the survey between October 2011 and February 2012 (HINTS cycle 4) was performed. We used logistic regression to evaluate the association between race/ethnicity and discussions around PSA. Less than 10% of the participants reported a prior PSA; Black and Hispanic men were more likely compared with White men. Compared with White men, Black and other race men reported receiving less communications from some doctors recommending PSA screening (ORblack: 0.16, 95% CIblack: 0.07-0.38; ORother: 0.10, 95% CIother: 0.04-0.25), and that no one is sure PSA testing saves lives (ORblack: 0.49, 95% CIblack: 0.04-6.91; ORother: 0.17, 95% CIother: 0.06-0.48). Minority men, while more likely to have had a PSA, were less likely to be told of the harms and benefits of PSA testing, compared with White men. Increasing communication surrounding screening advantages and disadvantages between providers and patients can increase awareness and knowledge among younger men. In a post-COVID-19 environment, communication regarding the return to preventative screenings within vulnerable populations is an important message to convey. Research shows preventive screenings have dropped across all population groups due to the pandemic yet the decline disproportionately affects Black and other minority men.


Subject(s)
COVID-19 , Prostatic Neoplasms , Adolescent , Adult , Communication , Cross-Sectional Studies , Decision Making , Early Detection of Cancer , Humans , Male , Mass Screening , Middle Aged , Prostate-Specific Antigen , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/prevention & control , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL